Updated Story Colorado’s prescription drug affordability board (PDAB) voted unanimously Friday (Feb. 23) to consider establishing an upper payment limit on Amgen’s psoriasis and arthritis drug Enbrel, and if the board follows through it would be the first in the nation to establish an upper payment limit for a drug. PDAB Chair Gail Mizner noted that the vote means the board begins the process of setting a UPL, but the process can be stopped at any time...